
China's first foreign-owned hospital seeks more medical tourists
Perennial Holdings Pte's US$139 million hospital opened earlier this year in the northern city of Tianjin, and is the first fully foreign-owned medical facility in the mainland. The hospital aims to derive 30% of its revenue during its first year of operation from patients visiting from Russia to the Middle East and South-East Asia - hoping China will become an emerging destination for medical tourism that can compete with established regional rivals Singapore, Thailand and Japan.
Perennial's focus on luring overseas patients to Tianjin came after China last year moved to allow private hospitals to be fully owned by foreign entities, which had previously needed a Chinese business partner.
China's health regulator has since encouraged the Tianjin facility to differentiate itself from the country's public hospitals, hospital president Daniel Liu said in an interview this week.
"Medical tourism has yet to become an industry in China, but it's showing promise. We hope to make the pie bigger,' he said.
"Some specialities in the Chinese healthcare system have grown in the past two decades, to a point that measures up to international standards.'
Private healthcare providers have faced headwinds operating in China as the country's post-Covid economic slump weighed on their main clientele - expats and well-off domestic customers with commercial insurance coverage. Some private hospitals and clinics have closed shop in recent months, while others have had to lower their prices, according to local media.
China can be appealing to medical tourists in part due to a speedier diagnosis and treatment process that can get slowed down by rigid referral systems and a lack of resources in other countries.
Still, luring global patients to China for treatment - especially when it comes to entering the country - still faces hurdles. China doesn't currently have a visa option for medical tourism, and the visa-free programme it's rolled out to more than 40 countries sometimes only grants stays of under a month - too short for some patients needing to undergo surgery and subsequent recovery.
Earlier this year, hospital chiefs and medical experts proposed creating a new visa for medical tourism at China's annual parliamentary session.
The move to expand medical tourism also dovetails with Beijing's goal to encourage more inbound travel.
Some northeast China hospitals are already frequented by patients from neighbouring Russia, while southern provinces are welcoming patients from South-East Asia as access to Chinese medical care becomes part of the government's tourism push, state agency Xinhua reported.
Perennial's Tianjin hospital is even hoping to bring in patients from as far as the UK, where private care is pricey and long waiting lists for the National Health Service have delayed treatments and even diagnoses of certain conditions.
To meet future demand from international clients, Perennial is working to recruit medical staff from Singapore and finalise global medical insurance coverage, Liu said. - Bloomberg

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
3 hours ago
- The Star
India aghast at Trump's ‘dead' economy jibe, 25% tariffs
NEW DELHI: Shock, dismay and angst swept across India as businesses, policymakers and citizens digested US President Donald Trump's sharp remarks and a surprise 25% tariff rate earlier this week. While Indian government officials weighed a response and business groups tallied the cost of the trade barrier, the local social media flared up with users protesting Trump's comments and criticising Indian Prime Minister Narendra Modi for not speaking up. It started with Trump saying that India's trade barriers were the "most strenuous and obnoxious,' in a Truth Social post July 30. He added the US may also impose a penalty for New Delhi's purchase of Russian weapons and energy. Less than a day later, he ripped into India again for aligning with Russia, calling them "dead economies' in another post. With no imminent trade deal, the 25% tariffs kicked in as of Friday. India is hardly alone in facing Trump's trade wrath - and not the subject to the very highest rates - but the news left business and political leaders wondering how to cope with the fallout. "Overnight, the US-India trade equation shifted from tense to turbulent,' said Akshat Garg, assistant vice president at Choice Wealth, a Mumbai based financial services firm. The levies "feel less like structured policy and more like a blunt-force political message.' Complicating the narrative around the India trade deal - or the lack of it - was the US pact with its traditional rival Pakistan that came through on the same day. As the US released rates across the world on Aug. 1, India's relative disadvantage to competitor exporting countries became more apparent, dampening moods and stoking tempers further. "The biggest blow is that Pakistan and Bangladesh got a better rate than us,' V. Elangovan, managing director at SNQS Internationals, an apparel maker in the south Indian manufacturing hub of Tirupur, told Bloomberg News. "We were expecting something in the 15 to 20% range.' India's annoyance can be traced back in part to Trump declaring himself the peacemaker that helped broker a ceasefire in the armed conflict between India and Pakistan in May. The move was seen as an effort to upstage Modi and put the two South Asian neighbours on an equal footing, despite India's larger military and economy. The events of this week have cemented that impression further in the eyes of some Indian observers. When the tariff rate news first dropped in late Wednesday evening in India, Ashish Kanodia recalls being "very disturbed.' A director at Kanodia Global, a closely held exporter that gets over 40% of its revenue from the US selling home fabrics to toys, the entrepreneur already has two of its largest US customers seeking discounts to make up for the levy. "The next six months are going to be difficult for everyone,' Kanodia said, adding that profit margins will be squeezed. If the pain continues for "months and months,' he said he'll have to start cutting his workforce. The US is India's largest trading partner, with the two-way trade between them at an estimated US$129.2 billion in 2024. Compared with India's 25%, Bangladesh was subjected to a 20% tariff, Vietnam got a 20% levy and Indonesia and Pakistan each received 19% duties. "We know that we have got a deal that is worse than other countries,' said Sabyasachi Ray, executive director at The Gem and Jewelry Export Promotion Council. "We will take it up with the government.' Trump's actions mark a 180-degree turn for New Delhi's hopes of preferential treatment over regional peers. It was among the first to engage Washington in trade talks in February, confident of hammering out a deal sooner than others. Trump had called India's Prime Minister Narendra Modi "my friend' in a Feb 14 post on X and the bond between the two countries "special.' India is now weighing options to placate the White House, including boosting US imports, Bloomberg News reported citing people familiar with the matter, and many hope that the bilateral relationship and the tariff rate can still be improved. "It is a storm in the India-US relationship at this moment but I think there's a good chance that it will go away,' Vivek Mishra, deputy director of the Strategic Studies Programme at Delhi based Observer Researcher Foundation, told Bloomberg News. Indian business and trade groups are supporting the government's stance on the deal as the negotiations for a US-India trade deal continue. Jewelry businesses "are worried but they are not panicking' because they hope a more favourable deal can be worked out, said Ray of the gems export body. "The negotiation that should be happening should be a win-win, not a win-lose.' The abrupt announcement by Trump over social media when negotiations with India were ongoing "seems like a knee-jerk reaction,' according to Rohit Kumar, founding partner at public policy research firm The Quantum Hub. "This appears to be a negotiating tactic aimed at unresolved discussion points,' Kumar said. - Bloomberg


New Straits Times
4 hours ago
- New Straits Times
Pfizer, BioNTech lose UK appeal to Moderna in Covid-19 vaccine patent fight
LONDON: US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms. It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech. "The judge made no error of law or principle" in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies. Pfizer quickly said it will appeal Friday's ruling to Britain's Supreme Court. "Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid," Pfizer said in a statement. "This decision has no immediate impact on Pfizer and BioNTech." Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed. Friday's decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland. Moderna said in a statement it was pleased with Friday's ruling and would "continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology." A UK court was told last year the firms had spent £19 million (US$25 million) fighting their legal battles. In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid pandemic. Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases. Traditional vaccines contain some form of the dead or inactivated target virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines. It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide "appropriate compensation."--AFP


New Straits Times
4 hours ago
- New Straits Times
Tesla ordered to pay US$242mil over fatal Autopilot crash
NEW YORK: A Florida jury on Friday ordered Tesla to pay hundreds of millions of dollars to plaintiffs who blamed a deadly 2019 crash on the company's "Autopilot" driver assistance technology. The jury found Tesla's system partly responsible for a crash in Key Largo that killed Naibel Benavides Leon and injured her boyfriend, Dillon Angulo, according to attorney Darren Jeffrey Rousso, a partner at the law firm that represented Angulo and Leon's family. The plaintiffs had alleged that Autopilot was to blame when driver George McGee's Tesla careened into a Chevrolet sport utility vehicle, killing Leon and injuring Angulo. The jury awarded US$200 million in punitive damages, plus US$59 million in compensatory damages to Leon's family and US$70 million in damages to Angulo, according to court records. Since the jury assigned one-third of the blame to Tesla, the compensatory damages will be reduced, Rousso said, with the total impact of the jury award totalling US$242 million after these reductions. "Justice was done," Rousso said. "The jury heard all the evidence and came up with a fair and just verdict on behalf of our clients." Tesla will appeal the decision, according to its defence attorneys. "Today's verdict is wrong and only works to set back automotive safety and jeapordise Tesla's and the entire industry's efforts to develop and implement life-saving technology," Tesla said through its legal team. "The evidence has always shown that this driver was solely at fault because he was speeding, with his foot on the accelerator – which overrode Autopilot – as he rummaged for his dropped phone without his eyes on the road," Tesla said. "To be clear, no car in 2019, and none today, would have prevented this crash. This was never about Autopilot."--AFP